keyword
https://read.qxmd.com/read/38568153/smek1-ablation-promotes-glucose-uptake-and-improves-obesity-related-metabolic-dysfunction-via-ampk-signaling-pathway
#21
JOURNAL ARTICLE
Shijun Wei, Yu Song, Zhengbin Li, Ai Liu, Yunfang Xie, Shang Gao, Hongbiao Shi, Ping Sun, Zekun Wang, Yecheng Jin, Wenjie Sun, Xi Li, Jiangxia Li, Qiji Liu
OBJECTIVE: Obesity has become a major risk of global public health. SMEK1 is also known as a regulatory subunit of protein phosphatase 4 (PP4). Both PP4 and SMEK1 have been clarified many metabolic functions, including regulating the hepatic gluconeogenesis and glucose transporter gene expression in yeast. Whether SMEK1 participates in obesity and the broader metabolic role in mammals is unknown. Thus we investigated the function of SMEK1 in white adipose tissue and glucose uptake. METHODS: GWAS/GEPIA/GEO database was used to analyze the correlation between SMEK1 and metabolic phenotypes/lipid metabolism related genes/obesity...
April 3, 2024: American Journal of Physiology. Endocrinology and Metabolism
https://read.qxmd.com/read/38562891/incretin-hormones-and-pharmacomimetics-rapidly-inhibit-agrp-neuron-activity-to-suppress-appetite
#22
Hayley E McMorrow, Carolyn M Lorch, Nikolas W Hayes, Stefan W Fleps, Joshua A Frydman, Jessica L Xia, Ricardo J Samms, Lisa R Beutler
Analogs of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) have become mainstays of obesity and diabetes management. However, both the physiologic role of incretin hormones in the control of appetite and the pharmacologic mechanisms by which incretin-mimetic drugs suppress caloric intake remain incompletely understood. Hunger-promoting AgRP-expressing neurons are an important hypothalamic population that regulates food intake. Therefore, we set out to determine how incretins analogs affect their activity in vivo ...
March 20, 2024: bioRxiv
https://read.qxmd.com/read/38556110/transcriptomic-profiling-of-sciatic-nerves-and-dorsal-root-ganglia-reveals-site-specific-effects-of-prediabetic-neuropathy
#23
JOURNAL ARTICLE
Stéphanie A Eid, Sarah E Elzinga, Kai Guo, Lucy M Hinder, John M Hayes, Crystal M Pacut, Emily J Koubek, Junguk Hur, Eva L Feldman
Peripheral neuropathy (PN) is a severe and frequent complication of obesity, prediabetes, and type 2 diabetes characterized by progressive distal-to-proximal peripheral nerve degeneration. However, a comprehensive understanding of the mechanisms underlying PN, and whether these mechanisms change during PN progression, is currently lacking. Here, gene expression data were obtained from distal (sciatic nerve; SCN) and proximal (dorsal root ganglia; DRG) injury sites of a high-fat diet (HFD)-induced mouse model of obesity/prediabetes at early and late disease stages...
March 29, 2024: Translational Research: the Journal of Laboratory and Clinical Medicine
https://read.qxmd.com/read/38554051/shining-a-spotlight-on-sarcopenia-and-myosteatosis-in-liver-disease-and-liver-transplantation-potentially-modifiable-risk-factors-with-major-clinical-impact
#24
REVIEW
Sophie Reichelt, Uta Merle, Miriam Klauss, Christoph Kahlert, Georg Lurje, Arianeb Mehrabi, Zoltan Czigany
Muscle-wasting and disease-related malnutrition are highly prevalent in patients with chronic liver diseases (CLD) as well as in liver transplant (LT) candidates. Alterations of body composition (BC) such as sarcopenia, myosteatosis and sarcopenic obesity and associated clinical frailty were tied to inferior clinical outcomes including hospital admissions, length of stay, complications, mortality and healthcare costs in various patient cohorts and clinical scenarios. In contrast to other inherent detrimental individual characteristics often observed in these complex patients, such as comorbidities or genetic risk, alterations of the skeletal muscle and malnutrition are considered as potentially modifiable risk factors with a major clinical impact...
March 30, 2024: Liver International: Official Journal of the International Association for the Study of the Liver
https://read.qxmd.com/read/38550382/liver-x-receptors-lxrs-in-cancer-an-eagle-s-view-on-molecular-insights-and-therapeutic-opportunities
#25
REVIEW
Prasanna Srinivasan Ramalingam, Sujatha Elangovan, Janaki Ramaiah Mekala, Sivakumar Arumugam
Cancer has become a serious health burden that results in high incidence and mortality rates every year, mainly due to various molecular alterations inside the cell. Liver X receptors (LXRs) dysregulation is one among them that plays a vital role in cholesterol metabolism, lipid metabolism and inflammation and also plays a crucial role in various diseases such as obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), cardiovascular diseases, Type 2 diabetes, osteoporosis, and cancer. Studies report that the activation of LXRs inhibits cancer growth by inhibiting cellular proliferation, inducing apoptosis and autophagy, regulating cholesterol metabolism, various signalling pathways such as Wnt, and PI3K/AKT, modulating the expression levels of cell-cycle regulators, and promoting antitumor immunity inside the tumor microenvironment...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38549461/taurine-activates-sirt1-ampk-foxo1-signaling-pathways-to-favorably-regulate-lipid-metabolism-in-c57bl6-obese-mice
#26
JOURNAL ARTICLE
Arya Devi Karikkakkavil Prakashan, Serva Peddha Muthukumar, Asha Martin
SCOPE: The identification of novel therapeutic agents capable of modulating lipid metabolism holds a promising potential in combating obesity and its associated complications. This study is conducted to evaluate the lipid lowering effect of dietary taurine administration on high-fat fed C57BL6 mice and to study the mechanism by which taurine impacts lipid metabolism. METHODS AND RESULTS: C57BL6 mice are grouped into four (n = 6): i) normal diet (ND), ii) a high-fat diet (HFD), iii) HFD + orlistat (STD), iv) HFD + taurine (TAU) group for 12 weeks...
March 29, 2024: Molecular Nutrition & Food Research
https://read.qxmd.com/read/38542065/regeneration-of-non-alcoholic-fatty-liver-cells-using-chimeric-fgf21-hgfr-a-novel-therapeutic-approach
#27
JOURNAL ARTICLE
Sung-Jun Kim, So-Jung Kim, Jeongeun Hyun, Hae-Won Kim, Jun-Hyeog Jang
Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant liver ailment attributed to factors like obesity and diabetes. While ongoing research explores treatments for NAFLD, further investigation is imperative to address this escalating health concern. NAFLD manifests as hepatic steatosis, precipitating insulin resistance and metabolic syndrome. This study aims to validate the regenerative potential of chimeric fibroblast growth factor 21 (FGF21) and Hepatocyte Growth Factor Receptor (HGFR) in NAFLD-afflicted liver cells...
March 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38540306/zebrafish-as-a-model-for-cardiovascular-and-metabolic-disease-the-future-of-precision-medicine
#28
REVIEW
Ramcharan Singh Angom, Naga Malleswara Rao Nakka
The zebrafish ( Danio rerio ) has emerged as an appreciated and versatile model organism for studying cardiovascular and metabolic diseases, offering unique advantages for both basic research and drug discovery. The genetic conservation between zebrafish and humans and their high fecundity and transparent embryos allow for efficient large-scale genetic and drug-oriented screening studies. Zebrafish possess a simplified cardiovascular system that shares similarities with mammals, making them particularly suitable for modeling various aspects of heart development, function, and disease...
March 20, 2024: Biomedicines
https://read.qxmd.com/read/38536964/lessons-from-insulin-policy-prescriptions-for-affordable-diabetes-and-obesity-medications
#29
REVIEW
Kathryn E Nagel, Reshma Ramachandran, Kasia J Lipska
Escalating insulin prices have prompted public scrutiny of the practices of drug manufacturers, pharmacy benefit managers, health insurers, and pharmacies involved in production and distribution of medications. As a result, a series of policies have been proposed or enacted to improve insulin affordability and foster greater equity in access. These policies have implications for other diabetes and obesity therapeutics. Recent legislation, at both the state and federal level, has capped insulin out-of-pocket payments for some patients...
March 27, 2024: Diabetes Care
https://read.qxmd.com/read/38532899/characterization-of-sensory-and-motor-dysfunction-and-morphological-alterations-in-late-stages-of-type-2-diabetic-mice
#30
JOURNAL ARTICLE
Ting Tian, Haofeng Li, Sensen Zhang, Maojun Yang
Diabetic neuropathy is the most common complication of diabetes and lacks effective treatments. Although sensory dysfunction during the early stages of diabetes has been extensively studied in various animal models, the functional and morphological alterations in sensory and motor systems during late stages of diabetes remain largely unexplored. In the current work, we examined the influence of diabetes on sensory and motor function as well as morphological changes in late stages of diabetes. The obese diabetic Leprdb/db mice (db/db) were used for behavioral assessments and subsequent morphological examinations...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38531438/capsaicin-induces-atp-dependent-thermogenesis-via-the-activation-of-trpv1-%C3%AE-3-ar-%C3%AE-1-ar-in-3t3-l1-adipocytes-and-mouse-model
#31
JOURNAL ARTICLE
Abdillah Alfin Mohammad, Jong Won Yun
Capsaicin (CAP) is a natural bioactive compound in chili pepper that activates the transient receptor potential vanilloid subfamily 1 (TRPV1) and is known to stimulate uncoupling protein 1 (UCP1)-dependent thermogenesis. However, its effect on ATP-dependent thermogenesis remains unknown. In this study, we employed qRT-PCR, immunoblot, staining method, and assay kit to investigate the role of CAP on ATP-dependent thermogenesis and its modulatory roles on the TRPV1, β3-adrenergic receptor (β3-AR), and α1-AR using in vitro and in vivo models...
March 24, 2024: Archives of Biochemistry and Biophysics
https://read.qxmd.com/read/38531211/glucagon-like-peptide-1-analogs-miracle-drugs-are-blooming
#32
REVIEW
Binbin Gong, Zhihong Yao, Chenxu Zhou, Wenxi Wang, Lidan Sun, Jing Han
Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on insulin secretion and gastric emptying positions it as a therapeutic linchpin. However, the limited applicability of native GLP-1 stems from its short half-life, primarily due to glomerular filtration and the inactivating effect of dipeptidyl peptidase-IV (DPP-IV). To address this, various structural modification strategies have been developed to extend GLP-1's half-life...
April 5, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38525190/case-report-of-belt-electrode-skeletal-muscle-electrical-stimulation-for-acute-heart-failure-with-severe-obesity-a-novel-therapeutic-option-for-acute-phase-rehabilitation
#33
Yuto Mochizuki, Takahiro Jimba, Syota Yasukawa, Aritomo Katsura, Akira Fukuda, Jiro Ando
BACKGROUND: Belt electrode skeletal muscle electrical stimulation (B-SES) is an emerging therapy anticipated to yield more favorable outcomes than conventional neuromuscular electrical stimulation (NMES), owing to its larger stimulation area. However, information on its efficacy and safety in patients with heart failure remains limited. CASE PRESENTATION: A 43-year-old man with a body mass index of 41 kg/m2 was admitted to our hospital for acute heart failure due to dilated cardiomyopathy...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38522954/the-association-between-monocyte-to-high-density-lipoprotein-cholesterol-ratio-and-chronic-kidney-disease-in-a-chinese-adult-population-a-cross-sectional-study
#34
JOURNAL ARTICLE
Lingling Xu, Dongling Li, Zongwei Song, Jin Liu, Yang Zhou, Junwei Yang, Ping Wen
BACKGROUND: Monocyte to high-density lipoprotein cholesterol ratio (MHR) was confirmed as a novel inflammatory marker and strongly associated with the risk of several diseases. This study aimed to investigate the relationship between MHR and chronic kidney disease (CKD) in a Chinese adult population. METHODS: In this cross-sectional study, 232,775 community-dwelling adults in Binhai who completed health checkups in 2021 were enrolled. Participants were categorized based on the MHR quartiles...
December 2024: Renal Failure
https://read.qxmd.com/read/38518995/human-recombinant-relaxin-2-serelaxin-regulates-the-proteome-lipidome-lipid-metabolism-and-inflammatory-profile-of-rat-visceral-adipose-tissue
#35
JOURNAL ARTICLE
Alana Aragón-Herrera, Sandra Feijóo-Bandín, Xocas Vázquez-Abuín, Laura Anido-Varela, Sandra Moraña-Fernández, Susana B Bravo, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Javier García-Seara, José Seijas, Diego Rodríguez-Penas, Daniele Bani, Oreste Gualillo, José Ramón González-Juanatey, Francisca Lago
Recombinant human relaxin-2 (serelaxin) has been widely proven as a novel drug with myriad effects at different cardiovascular levels, which support its potential therapeutic efficacy in several cardiovascular diseases (CVD). Considering these effects, together with the influence of relaxin-2 on adipocyte physiology and adipokine secretion, and the connection between visceral adipose tissue (VAT) dysfunction and the development of CVD, we could hypothesize that relaxin-2 may regulate VAT metabolism. Our objective was to evaluate the impact of a 2-week serelaxin treatment on the proteome and lipidome of VAT from Sprague-Dawley rats...
March 20, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38516814/review-article-new-developments-in-biomarkers-and-clinical-drug-development-in-alpha-1-antitrypsin-deficiency-related-liver-disease
#36
REVIEW
Rohit Loomba, Ginger Clark, Jeff Teckman, Veeral Ajmera, Cynthia Behling, Mark Brantly, David Brenner, Jeanine D'Armiento, Michael W Fried, Janani S Iyer, Mattias Mandorfer, Don C Rockey, Monica Tincopa, Raj Vuppalanchi, Zobair Younossi, Aleksander Krag, Alice M Turner, Pavel Strnad
BACKGROUND: Alpha-1 antitrypsin liver disease (AATLD) occurs in a subset of patients with alpha-1 antitrypsin deficiency. Risk factors for disease progression and specific pathophysiologic features are not well known and validated non-invasive assessments for disease severity are lacking. Currently, there are no approved treatments for AATLD. AIMS: To outline existing understanding of AATLD and to identify knowledge gaps critical to improving clinical trial design and development of new treatments...
March 22, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38514387/practical-strategies-to-manage-obesity-in-type-2-diabetes
#37
REVIEW
Helena W Rodbard, Katharine Barnard-Kelly, Andreas F H Pfeiffer, Carina Mauersberger, Oliver Schnell, Francesco Giorgino
The rising phenomenon of obesity, a major risk factor for the development and progression of type 2 diabetes, is a complex and multifaceted issue that requires a comprehensive and coordinated approach to be prevented and managed. Although novel pharmacological measures to combat obesity have achieved unprecedented efficacy, a healthy lifestyle remains essential for the long-term success of any therapeutic intervention. However, this requires a high level of intrinsic motivation and continued behavioural changes in the face of multiple metabolic, psychological and environmental factors promoting weight gain, particularly in the context of type 2 diabetes...
March 21, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38512816/dietary-pyruvate-targets-cytosolic-phospholipase-a2-to-mitigate-inflammation-and-obesity-in-mice
#38
JOURNAL ARTICLE
Sadaf Hasan, Nabil Ghani, Xiangli Zhao, Julia Good, Amanda Huang, Hailey Lynn Wrona, Jody Liu, Chuan-Ju Liu
Obesity has a multifactorial etiology and is known to be a state of chronic low-grade inflammation, known as meta-inflammation. This state is associated with the development of metabolic disorders such as glucose intolerance and nonalcoholic fatty liver disease. Pyruvate is a glycolytic metabolite and a crucial node in various metabolic pathways. However, its role and molecular mechanism in obesity and associated complications are obscure. In this study, we reported that pyruvate substantially inhibited adipogenic differentiation in vitro and its administration significantly prevented HFD-induced weight gain, white adipose tissue inflammation, and metabolic dysregulation...
March 21, 2024: Protein & Cell
https://read.qxmd.com/read/38509683/herbal-treatments-for-obesity-a-review
#39
JOURNAL ARTICLE
Amin Gasmi, Sadaf Noor, Pavan Kumar Mujawdiya, Muhammad Akram, Aisha Manzoor, Geir Bjørklund
Obesity is the most pervasive metabolic disorder, further linked with many other diseases, including diabetes, hypertension, cardiovascular disorders, and sleep apnea. To control the increasing weight of obese individuals, experts usually recommend exercise and lifestyle alterations, but medication and surgeries are also advised in severe cases. FDA-approved obesity-controlling drugs are effective but possess certain adverse effects, including dry mouth, drug abuse, dysregulation in monoamine neurotransmitters, insomnia, and many more...
March 20, 2024: Current Medicinal Chemistry
https://read.qxmd.com/read/38508416/impact-of-helicobacter-pylori-and-metabolic-syndrome-on-mast-cell-activation-related-pathophysiology-and-neurodegeneration
#40
REVIEW
Jannis Kountouras, Marina Boziki, Evangelos Kazakos, Paschalis Theotokis, Evangelia Kesidou, Maria Nella, Christos Bakirtzis, Eleni Karafoulidou, Elisabeth Vardaka, Maria C Mouratidou, Foteini Kyrailidi, Maria Tzitiridou-Chatzopoulou, Eirini Orovou, Evaggelia Giartza-Taxidou, Georgia Deretzi, Nikolaos Grigoriadis, Michael Doulberis
Both Helicobacter pylori (H. pylori) infection and metabolic syndrome (MetS) are highly prevalent worldwide. The emergence of relevant research suggesting a pathogenic linkage between H. pylori infection and MetS-related cardio-cerebrovascular diseases and neurodegenerative disorders, particularly through mechanisms involving brain pericyte deficiency, hyperhomocysteinemia, hyperfibrinogenemia, elevated lipoprotein-a, galectin-3 overexpression, atrial fibrillation, and gut dysbiosis, has raised stimulating questions regarding their pathophysiology and its translational implications for clinicians...
May 2024: Neurochemistry International
keyword
keyword
88482
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.